» Articles » PMID: 37664045

Feasibility to Use Whole-genome Sequencing As a Sole Diagnostic Method to Detect Genomic Aberrations in Pediatric B-cell Acute Lymphoblastic Leukemia

Abstract

Introduction: The suitability of whole-genome sequencing (WGS) as the sole method to detect clinically relevant genomic aberrations in B-cell acute lymphoblastic leukemia (ALL) was investigated with the aim of replacing current diagnostic methods.

Methods: For this purpose, we assessed the analytical performance of 150 bp paired-end WGS (90x leukemia/30x germline). A set of 88 retrospective B-cell ALL samples were selected to represent established ALL subgroups as well as ALL lacking stratifying markers by standard-of-care (SoC), so-called B-other ALL.

Results: Both the analysis of paired leukemia/germline (L/N)(n=64) as well as leukemia-only (L-only)(n=88) detected all types of aberrations mandatory in the current ALLTogether trial protocol, i.e., aneuploidies, structural variants, and focal copy-number aberrations. Moreover, comparison to SoC revealed 100% concordance and that all patients had been assigned to the correct genetic subgroup using both approaches. Notably, WGS could allocate 35 out of 39 B-other ALL samples to one of the emerging genetic subgroups considered in the most recent classifications of ALL. We further investigated the impact of high (90x; n=58) vs low (30x; n=30) coverage on the diagnostic yield and observed an equally perfect concordance with SoC; low coverage detected all relevant lesions.

Discussion: The filtration of the WGS findings with a short list of genes recurrently rearranged in ALL was instrumental to extract the clinically relevant information efficiently. Nonetheless, the detection of rearrangements required an additional customized analysis, due to multiple copies of this gene embedded in the highly repetitive D4Z4 region. We conclude that the diagnostic performance of WGS as the standalone method was remarkable and allowed detection of all clinically relevant genomic events in the diagnostic setting of B-cell ALL.

Citing Articles

Application of Omics Analyses in Pediatric B-Cell Acute Lymphoblastic Leukemia.

Vllahu M, Savarese M, Cantiello I, Munno C, Sarcina R, Stellato P Biomedicines. 2025; 13(2).

PMID: 40002837 PMC: 11852417. DOI: 10.3390/biomedicines13020424.


Ikaros Deletions among Bulgarian Patients with Acute Lymphoblastic Leukemia/Lymphoma.

Lozenov S, Tsoneva Y, Nikolaev G, Konakchieva R Diagnostics (Basel). 2024; 14(17).

PMID: 39272737 PMC: 11393869. DOI: 10.3390/diagnostics14171953.


Benefits for children with suspected cancer from routine whole-genome sequencing.

Hodder A, Leiter S, Kennedy J, Addy D, Ahmed M, Ajithkumar T Nat Med. 2024; 30(7):1905-1912.

PMID: 38956197 PMC: 11271414. DOI: 10.1038/s41591-024-03056-w.


Multimodal classification of molecular subtypes in pediatric acute lymphoblastic leukemia.

Krali O, Marincevic-Zuniga Y, Arvidsson G, Enblad A, Lundmark A, Sayyab S NPJ Precis Oncol. 2023; 7(1):131.

PMID: 38066241 PMC: 10709574. DOI: 10.1038/s41698-023-00479-5.

References
1.
Rausch T, Zichner T, Schlattl A, Stutz A, Benes V, Korbel J . DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012; 28(18):i333-i339. PMC: 3436805. DOI: 10.1093/bioinformatics/bts378. View

2.
Eisfeldt J, Vezzi F, Olason P, Nilsson D, Lindstrand A . , an efficient and comprehensive structural variant caller for massive parallel sequencing data. F1000Res. 2017; 6:664. PMC: 5521161. DOI: 10.12688/f1000research.11168.2. View

3.
Leongamornlert D, Gutierrez-Abril J, Lee S, Barretta E, Creasey T, Gundem G . Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia. Blood Adv. 2023; 7(15):3862-3873. PMC: 10405200. DOI: 10.1182/bloodadvances.2022008992. View

4.
Stanulla M, Cave H, Moorman A . IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?. Blood. 2019; 135(4):252-260. PMC: 7019035. DOI: 10.1182/blood.2019000813. View

5.
Inaba H, Azzato E, Mullighan C . Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children's Research Hospital Approach. Front Pediatr. 2017; 5:258. PMC: 5722984. DOI: 10.3389/fped.2017.00258. View